Subscribe
Chuck Scholtz, head of IP, Verdiva Bio
22 October 2025NewsBiotechnologyMarisa Woutersen

‘Doing more with less’: In-house counsel on budgets and strategy

Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025   Isomorphic Labs' head of IP shares why the first wave of AI-driven drug development stumbled, how data became pharma's most valuable currency, and why inventorship questions could make or break billion-dollar deals in machine learning.
Americas
Protect early, partner wisely: In-house tips for medtech startups
15 October 2025   In-house IP director at RefleXion talks about protecting complex medtech, why startups can't afford to cut corners on early decisions, and when to employ outside expertise.
Americas
Brazil’s patent shake-up: How pharma is handling a new reality
8 October 2025   A 2021 Supreme Court ruling changed how patent terms are calculated, forcing pharma companies to rethink their IP strategies. Juliana Neves of Licks explains the key changes, upcoming reforms, and how companies can protect their portfolios effectively.


Editor's picks

Data and delivery: Inside AI's inventorship dilemma
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025

Editor's picks

Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025
Americas
‘Death knell’ for investment: Universities warn against Lutnick’s royalty sharing proposal
13 October 2025
Americas
IP agencies vital to pharma and biotech grind to a halt
2 October 2025
Americas
Global vaccine patents rise, as data reveals shift in Big Pharma strategy
1 October 2025
Americas
Killing the golden goose of US drug innovation (Part II): Drug pricing myths
12 September 2025

More features

Less is more: patent lawyers flip the script after Amgen
End of the ‘Death Squad’? Squires puts PTAB on trial
Data and delivery: Inside AI's inventorship dilemma
Weil continues expansion with top trade secrets litigator
Top pharma, biotech, and medtech experts gather at LSPN Fall
Mitsubishi Tanabe doubles down on Radicava protection
‘All it takes is a post on Truth Social’: Is this patent reform's moment?
Novartis fails to block repackaged imports of blockbuster treatment